Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes - PubMed (original) (raw)
Review
Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes
Nathalie Vigneron et al. Cell Mol Life Sci. 2011 May.
Abstract
The molecular definition of tumor antigens recognized by cytolytic T lymphocytes (CTL) started in the late 1980s, at a time when the MHC class I antigen processing field was in its infancy. Born together, these two fields of science evolved together and provided each other with critical insights. Over the years, stimulated by the potential interest of tumor antigens for cancer immunotherapy, scientists have identified and characterized numerous antigens recognized by CTL on human tumors. These studies have provided a wealth of information relevant to the mode of production of antigenic peptides presented by MHC class I molecules. A number of tumor antigenic peptides were found to result from unusual mechanisms occurring at the level of transcription, translation or processing. Although many of these mechanisms occur in the cell at very low level, they are relevant to the immune system as they determine the killing of tumor cells by CTL, which are sensitive to low levels of peptide/MHC complexes. Moreover, these unusual mechanisms were found to occur not only in tumor cells but also in normal cells. Thereby, the study of tumor antigens has illuminated many aspects of MHC class I processing. We review here those insights into the MHC I antigen processing pathway that result from the characterization of human tumor antigens recognized by CTL.
Figures
Fig. 1
Pathways for processing and presentation of class I-restricted tumor antigens. CTL recognize on tumor cells antigenic peptides that are produced through a variety of unconventional processes, including aberrant transcription or mRNA splicing (1, 2), translation of alternative or cryptic open reading frames (3) or post-translational modifications (12). Proteins are targeted for degradation by the proteasome after the addition of ubiquitin chains by ubiquitin ligases (4). Surprisingly, proteasomes also produce antigenic peptides by splicing fragments that are originally non-contiguous in the parental protein (5). In the cytosol, additional proteases were found to produce or destroy antigenic peptides (6, 7). Peptides produced in the cytosol are then transported in the ER lumen by the transporter TAP (8), where they can be further trimmed by ER aminopeptidases such as ERAP1 or 2 (9). Peptides with the appropriate length and HLA binding motif are loaded onto MHC I molecules with the help of the peptide loading complex (10). The signal sequences of ER-targeted proteins also contain antigenic peptides: following cleavage of the signal sequence by the signal peptidase and the signal peptide peptidase (11), those peptides are released in the ER lumen and loaded onto MHC I independently of TAP. Membrane or secreted proteins also produce MHC class I binding peptides. Tyrosinase is a type I transmembrane protein, which supplies an antigenic peptide containing an aspartate instead of the genetically encoded asparagine. This peptide is produced after glycosylation of the tyrosinase protein in the ER, its retrotranslocation into the cytosol where it is deglycosylated and degraded by proteasome. Removal of the glycan moiety by peptide _N_-glycanase leads to deamidation of the asparagine into an aspartate residue, which is contained in the antigenic peptide presented by melanoma cells (12, 13). A peptide originating from secreted matrix metalloprotease-2 was found to be processed by the proteasome after endocytosis. After secretion, activation of pro-MMP-2 into mature MMP2 appears to be required for adequate processing of the antigenic peptide. Following endocytosis, the MMP-2 protein would be released in the cytosol and degraded by the proteasome (14)
Fig. 2
Model of the peptide splicing reaction inside the proteasome. Mechanism of production of the spliced the peptide RTKQLYPEW derived from gp100 (a) and the spliced peptide SLPRGTSTPK derived from SP110 (b). The balls represent the catalytic β-subunits of proteasomes with the hydroxyl group of the side chain of the N-terminal threonine
Similar articles
- Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.
Mester G, Hoffmann V, Stevanović S. Mester G, et al. Cell Mol Life Sci. 2011 May;68(9):1521-32. doi: 10.1007/s00018-011-0659-9. Epub 2011 Mar 9. Cell Mol Life Sci. 2011. PMID: 21387142 Free PMC article. Review. - Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M, Mezquita L, Guillebot De Nerville G, Tihy I, Malenica I, Chouaib S, Mami-Chouaib F. Leclerc M, et al. Front Immunol. 2019 Jul 3;10:1505. doi: 10.3389/fimmu.2019.01505. eCollection 2019. Front Immunol. 2019. PMID: 31333652 Free PMC article. Review. - Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S, Kumari S, Fallang LE, Sand KM, Yang W, Landsverk OJ, Bakke O, Olweus J, Gregers TF. Wälchli S, et al. Eur J Immunol. 2014 Mar;44(3):774-84. doi: 10.1002/eji.201343671. Epub 2013 Dec 27. Eur J Immunol. 2014. PMID: 24293164 - B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.
Johnston JV, Malacko AR, Mizuno MT, McGowan P, Hellström I, Hellström KE, Marquardt H, Chen L. Johnston JV, et al. J Exp Med. 1996 Mar 1;183(3):791-800. doi: 10.1084/jem.183.3.791. J Exp Med. 1996. PMID: 8642283 Free PMC article. - Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway.
Carbonetti NH, Irish TJ, Chen CH, O'Connell CB, Hadley GA, McNamara U, Tuskan RG, Lewis GK. Carbonetti NH, et al. Infect Immun. 1999 Feb;67(2):602-7. doi: 10.1128/IAI.67.2.602-607.1999. Infect Immun. 1999. PMID: 9916065 Free PMC article.
Cited by
- mRNA-Based Therapeutics in Cancer Treatment.
Sun H, Zhang Y, Wang G, Yang W, Xu Y. Sun H, et al. Pharmaceutics. 2023 Feb 13;15(2):622. doi: 10.3390/pharmaceutics15020622. Pharmaceutics. 2023. PMID: 36839944 Free PMC article. Review. - At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention.
Tundo GR, Sbardella D, Oddone F, Kudriaeva AA, Lacal PM, Belogurov AA Jr, Graziani G, Marini S. Tundo GR, et al. Cancers (Basel). 2021 Sep 28;13(19):4852. doi: 10.3390/cancers13194852. Cancers (Basel). 2021. PMID: 34638337 Free PMC article. Review. - Neo-Antigen mRNA Vaccines.
Esprit A, de Mey W, Bahadur Shahi R, Thielemans K, Franceschini L, Breckpot K. Esprit A, et al. Vaccines (Basel). 2020 Dec 18;8(4):776. doi: 10.3390/vaccines8040776. Vaccines (Basel). 2020. PMID: 33353155 Free PMC article. Review. - The Landscape of Tumor-Specific Antigens in Colorectal Cancer.
Rus Bakarurraini NAA, Ab Mutalib NS, Jamal R, Abu N. Rus Bakarurraini NAA, et al. Vaccines (Basel). 2020 Jul 10;8(3):371. doi: 10.3390/vaccines8030371. Vaccines (Basel). 2020. PMID: 32664247 Free PMC article. Review. - Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process.
Feola S, Chiaro J, Martins B, Cerullo V. Feola S, et al. Cancers (Basel). 2020 Jun 23;12(6):1660. doi: 10.3390/cancers12061660. Cancers (Basel). 2020. PMID: 32585818 Free PMC article. Review.
References
- Townsend AR, Gotch FM, Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell. 1985;42(2):457–467. - PubMed
- Lurquin C, Van Pel A, Mariame B, et al. Structure of the gene of tum—transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell. 1989;58(2):293–303. - PubMed
- Falk K, Rotzschke O, Stevanovic S, et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991;351(6324):290–296. - PubMed
- Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Intl J Cancer. 1999;80(2):219–230. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials